Related Experiment Video
Updated: Jan 22, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Carrier-Enhanced Anticancer Efficacy of Sunitinib-Loaded Green Tea-Based Micellar Nanocomplex beyond Tumor-Targeted
Nunnarpas Yongvongsoontorn1, Joo Eun Chung1, Shu Jun Gao1
1Institute of Bioengineering and Nanotechnology , 31 Biopolis Way, The Nanos, #07-01 , Singapore 138669.
Abstract:
Although a few nanomedicines have been approved for clinical use in cancer treatment, that recognizes improved patient safety through targeted delivery, their improved efficacy over conventional drugs has remained marginal. One of the typical drawbacks of nanocarriers for cancer therapy is a low drug-loading capacity that leads to insufficient efficacy and requires an increase in dosage and/or frequency of administration, which in turn increases carrier toxicity. In contrast, elevating drug-loading would cause the risk of nanocarrier instability, resulting in low efficacy and off-target toxicity. This intractable drug-to-carrier ratio has imposed constraints on the design and development of nanocarriers. However, if the nanocarrier has intrinsic therapeutic effects, the efficacy would be synergistically augmented with less concern for the drug-to-carrier ratio. Sunitinib-loaded micellar nanocomplex (SU-MNC) was formed using poly(ethylene glycol)-conjugated epigallocatechin-3-O-gallate (PEG-EGCG) as such a carrier. SU-MNC specifically inhibited the vascular endothelial growth factor-induced proliferation of endothelial cells, exhibiting minimal cytotoxicity to normal renal cells. SU-MNC showed enhanced anticancer effects and less toxicity than SU administered orally/intravenously on human renal cell carcinoma-xenografted mice, demonstrating more efficient effects on anti-angiogenesis, apoptosis induction, and proliferation inhibition against tumors. In comparison, a conventional nanocarrier, SU-loaded polymeric micelle (SU-PM) comprised of PEG-b-poly(lactic acid) (PEG-PLA) copolymer, only reduced toxicity with no elevated efficacy, despite comparable drug-loading and tumor-targeting efficiency to SU-MNC. Improved efficacy of SU-MNC was ascribed to the carrier-drug synergies with the high-performance carrier of PEG-EGCG besides tumor-targeted delivery.
Insights
This study introduces a novel nanomedicine carrier, sunitinib-loaded micellar nanocomplex (SU-MNC), which enhances cancer treatment efficacy and reduces toxicity. The unique carrier synergizes with the drug, improving outcomes in preclinical models.
Area of Science:
- Nanomedicine
- Cancer Therapy
- Drug Delivery
Background:
- Current nanomedicines for cancer show limited efficacy gains over conventional drugs.
- Low drug-loading capacity and carrier instability are key challenges in nanocarrier design.
- Intrinsic therapeutic properties of nanocarriers can overcome drug-to-carrier ratio limitations.
Purpose of the Study:
- To develop and evaluate a novel nanomedicine, sunitinib-loaded micellar nanocomplex (SU-MNC), using a poly(ethylene glycol)-conjugated epigallocatechin-3-O-gallate (PEG-EGCG) carrier.
- To assess the synergistic therapeutic effects and safety profile of SU-MNC compared to conventional sunitinib formulations.
- To investigate the underlying mechanisms of enhanced efficacy, including anti-angiogenesis and apoptosis induction.
Main Methods:
- Formulation of SU-MNC using PEG-EGCG as the carrier.
- In vitro assessment of SU-MNC's effect on endothelial cell proliferation and cytotoxicity.
- In vivo evaluation of SU-MNC's anticancer effects and toxicity in human renal cell carcinoma-xenografted mice.
- Comparison of SU-MNC with sunitinib-loaded polymeric micelles (SU-PM) and orally/intravenously administered sunitinib.
Main Results:
- SU-MNC specifically inhibited vascular endothelial growth factor-induced endothelial cell proliferation with minimal cytotoxicity to normal renal cells.
- SU-MNC demonstrated enhanced anticancer effects and reduced toxicity in mice compared to conventional sunitinib administration.
- SU-MNC exhibited superior anti-angiogenesis, apoptosis induction, and proliferation inhibition against tumors.
- SU-MNC showed improved efficacy attributed to carrier-drug synergy, unlike SU-PM which only reduced toxicity.
Conclusions:
- The PEG-EGCG carrier provides intrinsic therapeutic benefits, enhancing sunitinib efficacy beyond simple drug delivery.
- SU-MNC represents a promising nanomedicine strategy for improved cancer therapy with a favorable safety profile.
- Carrier-drug synergy is a critical factor for overcoming the limitations of traditional nanocarrier designs in cancer treatment.
Related Concept Videos
01:24Electron Carriers
Over the many stages of cellular respiration, glucose breaks down into carbon dioxide and water. Electron carriers pick up electrons lost by glucose in these reactions, temporarily storing and releasing them into the electron...
01:21Carrier Transport
Drift Current:
The drift of charge carriers is started by an external electric field (E). Charged particles, such as electrons and holes, experience an acceleration between collisions with lattice atoms. For electrons, this results in a drift velocity (vd) given by:
01:29Self-Efficacy
01:21Green Algae
01:06Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
01:22Carrier Generation and Recombination
This process is given by the generation rate G and is efficient due to the conservation of momentum between the valence band maximum and conduction band minimum.
Indirect generation involves an...